Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
HOME > BUSINESS
BUSINESS
- Pfizer to Enjoy Monopoly in Asacol Generic Market until December
September 14, 2015
- Fluvoxamine Shows Significant Difference against Placebo for Pediatric Obsessive-Compulsive Disorder in PIII Study: Meiji Seika Pharma
September 14, 2015
- FDA Grants Priority Review Status to Multiple Myeloma Drug Ixazomib: Takeda
September 11, 2015
- Ethical Drug Sales Up 6.5% in July: Crecon Report
September 10, 2015
- MTPC, Biogen Partner Up on Imusera Successor
September 10, 2015
- Sanwa Kagaku, Ube to Codevelop Pruritus Treatment
September 10, 2015
- Clinical Study of JACE for Giant Pigmented Nevus Completed: J-TEC
September 9, 2015
- Sanofi Rolls Out Plaquenil, Lantus XR in Japan
September 8, 2015
- FDA Grants Breakthrough Therapy Designation to Hemophilia A Treatment ACE910: Chugai
September 7, 2015
- MSD Paid 13 Billion Yen to Doctors, Medical Institutions in 2014
September 3, 2015
- Merck Serono Japan Wants to Be Leader in Oncology, Fertility: President
September 3, 2015
- Towa to Improve Production Efficiencies and Facilities at Yamagata Plant in Response to Rising Generic Demand
September 3, 2015
- AZ, Daiichi Sankyo Team Up for Development, Commercialization of Nasal Flu Vaccine in Japan
September 3, 2015
- GSK Adjusts Shipments of Hepatitis B Treatment Tenozet Due to Disaster-Stricken Plant Following Tianjin Explosion in China
September 2, 2015
- Pfizer Japan Slapped with Biz Improvement Order over ADR Reporting
September 2, 2015
- Sanofi Names Former Keio University Professor Yuji Sato as R&D Head
September 2, 2015
- Eisai to Develop Insomnia Treatment Lemborexant with Purdue Pharma of US
September 2, 2015
- Genzyme Japan Launches Oral Gaucher’s Disease Treatment Cerdelga
September 2, 2015
- Harvoni, Yervoy, Other New Drugs Hit Japan Market
September 1, 2015
- Baxalta Japan Aims for 6-8% Annual Growth by 2020: President Kawamoto
September 1, 2015
ページ
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…